Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen

NCT01124695 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT01124695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01124695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Completed
Start date
January 7, 2011
Completion date
December 31, 2022
Enrollment
124 (actual)
Sites
294

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, stage iv breast cancer